Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4

Trial Details

NCT ID
NCT06781983
Phase
PHASE1
Sponsor
Innate Pharma
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • IPH4502
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • New York, New York, United States|40.71427,-74.00597
  • Dallas, Texas, United States|32.78306,-96.80667
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that are known to express Nectin-4
  • Prior systemic treatment for locally advanced or metastatic disease, yet no therapy with demonstrated clinical benefit for the tumor type is availa…
  • Measurable disease according to RECIST 1.1.
  • Archival tumor tissue obtained within 4 months of screening and since the last anticancer therapy prior to the study or agree to undergo a tumor bi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →